Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Visit NurExone Biologic Inc.

NurExone is aiming to revolutionize recovery from nervous system injuries by regenerating and rewiring of neurons.



Bullboard - Investor Discussion Forum NurExone Biologic Inc. V.NRX

Alternate Symbol(s):  NRXBF

Healthcare Biotechnology
NurExone Biologic Inc. is a pharmaceutical company. The Company is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active... see more

TSXV:NRX - Post Discussion

NurExone Biologic Inc. > 🧬 Exosome Therapy Milestone 🧬
View:
Post by cmarketinsights on Jan 14, 2025 5:56pm

🧬 Exosome Therapy Milestone 🧬

NurExone has secured a master cell bank for its innovative exosome-based therapy, ExoPTEN, targeting acute spinal cord injury (SCI). With Orphan Drug Designation from the FDA and EMA, phase one trials are on the horizon for 2025.

 

Dive deeper into NurExone’s breakthrough

Be the first to comment on this post
NurExone Biologic Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.NRX

Visit Facebook Visit X Visit Linked In Visit Youtube



PRESENTATION TECHNOLOGY - EXOSOMES TECHNOLOGY - EXOTHERAPY MANAGEMENT ANALYST REPORT LEARN ABOUT ODD

Investor Presentation

View the Presentation

Investment Opportunity

NurExone operates according to two business lines – Development of a first exosome-based therapy for acute Spinal Cord Injuries (SCI).

In parallel, the company is monetizing its proprietary ExoTherapy platform through licensing to the global biopharmaceutical industry to deliver therapies for other diseases and indications.

The company’s first product, ExoPTEN, for acute spinal cord injury, has been granted Orphan Drug Designation by the FDA.



The Watchlist

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Why NurExone??

The Ultimate Drug Delivery System

The Beginning of NurExone

Facebook

Contact Us

Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com

Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com

Dr. Eva Reuter Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu